Medarex to Present at the UBS Global Life Sciences Conference

Thursday, September 18, 2008 General News J E 4
PRINCETON, N.J., Sept. 17 Medarex, Inc.(Nasdaq: MEDX) announced today that it is scheduled to present at the UBSGlobal Life Sciences Conference at 4:30 p.m. Eastern Time on Monday, September22, 2008. The event will be webcast live and will be available in the InvestorRelations section of the Medarex website at An archivededition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery,development and potential commercialization of fully human antibody-basedtherapeutics to treat life-threatening and debilitating diseases, includingcancer, inflammation, autoimmune disorders and infectious diseases. Medarexapplies its UltiMAb(R) technology and product development and clinicalmanufacturing experience to generate, support and potentially commercialize abroad range of fully human antibody product candidates for itself and itspartners. More than 40 of these therapeutic product candidates derived fromMedarex technology are in human clinical testing or have had INDs submittedfor such trials, with seven of the most advanced product candidates currentlyin Phase 3 clinical trials or the subject of regulatory applications formarketing authorization. Medarex is committed to building value by developinga diverse pipeline of antibody products to address the world's unmethealthcare needs. For more information about Medarex, visit its Web site at

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks ofMedarex, Inc. All rights are reserved.

SOURCE Medarex, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Telik Announces Presentation and Webcast at UBS Gl...
Baxter International Third Quarter 2008 Financial ...